<DOC>
	<DOCNO>NCT01288404</DOCNO>
	<brief_summary>Hypothesis : Subconjunctival bevacizumab injection may potentially suppress neovascularization pterygium , prevent retard progression recurrence .</brief_summary>
	<brief_title>Randomized Controlled Trial Subconjunctival Bevacizumab Injection Impending Recurrent Pterygium</brief_title>
	<detailed_description>1 . Impending recurrent pterygium 2 . Anti-VEGF therapy - Bevacizumab - Subconjunctival injection - Suppress neovascularization</detailed_description>
	<mesh_term>Pterygium</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Fluorometholone</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Tetrahydrozoline</mesh_term>
	<criteria>1 . Impending recurrent pterygium develop within 6 month follow pterygium surgery either simple excision excision graft . 2 . Failure conventional topical antiinflammatory therapy impend recurrent pterygium define progression fibrovascular tissue excise area despite receive treatment . 3 . No history adjunctive treatment MMC , 5FU , periocular injection corticosteroid beta radiation . 4 . No ocular surface pathology coexist ocular disease . 5 . No ocular surgery within previous 6 month . 6 . No history allergy medication use study . 7 . Good compliance study regimen availability duration entire study period . 1 . Platelet disorder 2 . Hypertension 3 . Pregnant lactating woman</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Bevacizumab , impend recurrent pterygium</keyword>
</DOC>